Table 1.
Baseline characteristics of breast cancer patients after anti-HER2-tageted therapy
| Trastuzumab (n = 40) |
Trastuzumab + pertuzumab (n = 40) |
P value | |
|---|---|---|---|
| Demographics | |||
| Age (years) | 54.0 ± 9.2 | 53.7 ± 10.3 | 0.654 |
| BMI (kg/m2) | 24.8 ± 3.1 | 24.5 ± 3.4 | 0.538 |
| Cardiovascular risk factors | |||
| Hypertension | 3(7.5%) | 4(10%) | 0.462 |
| Diabetes mellitus | 2(5%) | 3(7.5%) | 0.389 |
| Dyslipidemia | 2(5%) | 3(7.5%) | 0.389 |
| Coronary heart disease | 0 | 0 | - |
| Vital sign | |||
| Systolic blood pressure (mmHg) | 123.3 ± 13.6 | 121.5 ± 15.3 | 0.674 |
| Diastolic blood pressure (mmHg) | 77.1 ± 9.8 | 76.8 ± 8.8 | 0.728 |
| Therapies | |||
| Anthracycline use | 30(75%) | 20(50%) | 0.357 |
| Left-side radiotherapy | 12(30%) | 15(37.5%) | 0.433 |